Author

Christopher M. Booth

h-index 8 View on Semantic Scholar

We have 2 of 26 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

(Neo)adjuvant approvals for solid tumors by the US Food and Drug Administration 2010-2023

Abstract Background (Neo)adjuvant systemic treatments aim to improve overall survival by reducing recurrence risk; however, there can be challenges, such as reliance on surrogate endpoints, censoring, loss to follow-up, and impact on quality of life. We examine the design, reporting, and outcomes of US Food and Drug Ad...

C. M. Valiente, A. Mittal, Dong-Sheng Tu et al. · Journal of the National Canc... · 0 citations

Open access Aug 2026

The diagnosis to surgery interval and overall survival in patients with cervical cancer.

It was found that prolonged DTIs to be significantly associated with poorer survival, but cautious interpretation of the results is needed given the potential impact of the waiting time paradox.

M. Jalink, W. King, Christopher M. Booth et al. · Cancer Epidemiology · 0 citations